Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:COGTNASDAQ:EOLSNASDAQ:EPZMNASDAQ:FSIINASDAQ:RLMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$6.61+1.2%$6.97$3.67▼$13.50$631.98M1.52.07 million shs1.05 million shsEOLSEvolus$11.56-0.7%$13.64$7.07▼$15.43$669.79M1.45629,337 shs341,706 shsEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsFSIIFS Development Corp. II$9.80$11.34$9.64▼$15.05$203.13MN/A99,758 shs289,188 shsRLMDRelmada Therapeutics$4.30-8.1%$5.29$2.36▼$7.22$129.73M0.19256,873 shs86,188 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+1.23%+0.92%-1.78%+44.01%-41.30%EOLSEvolus-0.69%-8.90%-17.31%-2.45%+38.28%EPZMEpizyme0.00%0.00%0.00%0.00%0.00%FSIIFS Development Corp. II0.00%0.00%0.00%0.00%0.00%RLMDRelmada Therapeutics-8.12%-7.73%-19.93%+25.00%+53.02%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences1.639 of 5 stars4.41.00.00.01.80.00.6EOLSEvolus4.1533 of 5 stars3.53.00.03.53.22.50.6EPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AFSIIFS Development Corp. IIN/AN/AN/AN/AN/AN/AN/AN/ARLMDRelmada Therapeutics2.6497 of 5 stars2.02.00.04.40.03.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences2.71Moderate Buy$13.67106.76% UpsideEOLSEvolus3.00Buy$20.6078.20% UpsideEPZMEpizymeN/AN/AN/AN/AFSIIFS Development Corp. IIN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/A$25.00481.40% UpsideCurrent Analyst RatingsLatest EOLS, FSII, EPZM, RLMD, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/1/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.002/27/2024COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $20.002/26/2024COGTCogent BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.002/26/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.002/26/2024COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$14.00 ➝ $8.002/23/2024COGTCogent BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$5.00 ➝ $10.002/22/2024COGTCogent BiosciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/12/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.002/8/2024COGTCogent BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.001/29/2024EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AEOLSEvolus$202.09M3.31N/AN/A($0.36) per share-32.11EPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72FSIIFS Development Corp. IIN/AN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$2.84 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$192.41M-$2.40N/AN/AN/AN/A-86.67%-58.11%5/14/2024 (Estimated)EOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/14/2024 (Estimated)EPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AFSIIFS Development Corp. IIN/AN/A0.00∞N/AN/AN/AN/AN/ARLMDRelmada Therapeutics-$98.79M-$3.28N/AN/AN/AN/A-93.44%-85.11%5/9/2024 (Estimated)Latest EOLS, FSII, EPZM, RLMD, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2024Q4 2023RLMDRelmada Therapeutics-$0.88-$0.84+$0.04-$0.84N/AN/A3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 million2/26/202412/31/2023COGTCogent Biosciences-$0.55-$0.63-$0.08-$0.63N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AFSIIFS Development Corp. IIN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A7.097.09EOLSEvolusN/A2.332.10EPZMEpizymeN/A5.355.19FSIIFS Development Corp. IIN/A0.230.23RLMDRelmada TherapeuticsN/A8.008.00OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AEOLSEvolus90.69%EPZMEpizyme76.45%FSIIFS Development Corp. II84.57%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences5.10%EOLSEvolus5.40%EPZMEpizyme23.40%FSIIFS Development Corp. IIN/ARLMDRelmada Therapeutics13.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences16495.61 million90.74 millionOptionableEOLSEvolus27357.94 million54.82 millionOptionableEPZMEpizyme250168.33 million128.97 millionOptionableFSIIFS Development Corp. II320.73 millionN/ANot OptionableRLMDRelmada Therapeutics2030.17 million26.10 millionOptionableEOLS, FSII, EPZM, RLMD, and COGT HeadlinesSourceHeadlineRELMADA THERAPEUT.DL-,001 (4E2.F)finance.yahoo.com - April 16 at 7:48 AMRelmada Therapeutics: Run Up Into Results May Resume Following This Dropseekingalpha.com - March 21 at 9:39 PMOptimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stabilitymarkets.businessinsider.com - March 21 at 9:38 AMRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 20 at 3:29 PMRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 20 at 8:50 AMQ4 2023 Relmada Therapeutics Inc Earnings Callfinance.yahoo.com - March 20 at 8:50 AMRLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023investorplace.com - March 19 at 10:01 PMRecap: Relmada Therapeutics Q4 Earningsbenzinga.com - March 19 at 5:41 PMRelmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Resultsfinance.yahoo.com - March 19 at 5:41 PMRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Resultsprnewswire.com - March 19 at 4:15 PMOptions Volatility and Implied Earnings Moves Today, March 19, 2024msn.com - March 19 at 12:40 PMRelmada Therapeutics FY 2023 Earnings Previewmsn.com - March 18 at 7:48 PMRLMD Apr 2024 2.500 putfinance.yahoo.com - March 16 at 7:13 PMRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conferenceprnewswire.com - March 5 at 7:30 AMRelmada Therapeutics Inc (RLMD)investing.com - February 13 at 5:44 PMAnalysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)markets.businessinsider.com - February 5 at 2:22 PMRelmada Therapeutics Inc.thestreet.com - February 4 at 7:57 AMRelmada Therapeutics And 2 Other Penny Stocks Insiders Are Buyingmsn.com - February 2 at 8:12 AMRelmada Therapeutics Shares Hit 52-Week High After Execs Buy Sharesmarketwatch.com - February 1 at 7:49 PMRelmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Sharesfinance.yahoo.com - February 1 at 3:42 PMRelmada Therapeutics Stock (NASDAQ:RLMD) Dividends: History, Yield and Datesbenzinga.com - January 30 at 4:34 PMRelmada Therapeutics Inc RLMDmorningstar.com - January 23 at 9:16 PMRelmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutionsfinance.yahoo.com - January 23 at 9:10 AMMizuho sees weakness in Relmada Therapeutics shares as buying opportunityrealmoney.thestreet.com - January 4 at 11:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCogent BiosciencesNASDAQ:COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.EpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.FS Development Corp. IINASDAQ:FSIIFS Development Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.Relmada TherapeuticsNASDAQ:RLMDRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.